| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 6.8% | $2,525,900 | 2,122,605 | Sands Capital Life Sciences Pulse Fund II, L.P. | 30 Jun 2025 | |||
| CITADEL ADVISORS LLC | 5.5% | +12% | $3,116,579 | +$326,709 | 1,721,867 | +12% | Kenneth Griffin | 14 Nov 2025 |
As of 31 Dec 2025, 48 institutional investors reported holding 18,610,735 shares of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV). This represents 59% of the company’s total 31,306,673 outstanding shares.
The largest institutional shareholders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) together control 59% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 27% | 8,340,508 | 0% | 0.21% | $20,100,624 |
| Sands Capital Alternatives, LLC | 6.8% | 2,122,605 | 0% | 0.99% | $5,115,478 |
| CITADEL ADVISORS LLC | 5.2% | 1,641,884 | +6.5% | 0% | $3,956,941 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.8% | 888,130 | 0% | 0% | $2,140,393 |
| VANGUARD GROUP INC | 2.2% | 698,857 | +12% | 0% | $1,684,246 |
| RENAISSANCE TECHNOLOGIES LLC | 2% | 634,169 | +1.7% | 0% | $1,528,347 |
| TWO SIGMA INVESTMENTS, LP | 1.9% | 585,069 | +83% | 0% | $1,410,016 |
| ACADIAN ASSET MANAGEMENT LLC | 1.9% | 581,208 | +532% | 0% | $1,400,000 |
| MARSHALL WACE, LLP | 1.6% | 496,081 | +231% | 0% | $1,195,556 |
| ACORN CAPITAL ADVISORS, LLC | 1.3% | 405,237 | 0% | 0.33% | $976,622 |
| UBS Group AG | 1.1% | 348,541 | -49% | 0% | $839,984 |
| JANE STREET GROUP, LLC | 1.1% | 342,071 | +18% | 0% | $824,391 |
| TWO SIGMA ADVISERS, LP | 1.1% | 333,773 | +145% | 0% | $804,393 |
| BlackRock, Inc. | 0.66% | 205,124 | -38% | 0% | $494,349 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.63% | 198,223 | +3.2% | 0% | $477,891 |
| MILLENNIUM MANAGEMENT LLC | 0.39% | 121,524 | -34% | 0% | $292,873 |
| GOLDMAN SACHS GROUP INC | 0.38% | 119,422 | +505% | 0% | $287,807 |
| STATE STREET CORP | 0.21% | 67,145 | 0% | 0% | $161,819 |
| NORTHERN TRUST CORP | 0.2% | 63,718 | +51% | 0% | $153,561 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.15% | 48,015 | 0.01% | $115,716 | |
| MORGAN STANLEY | 0.15% | 46,831 | -18% | 0% | $112,863 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.14% | 42,900 | +87% | 0% | $103,389 |
| Squarepoint Ops LLC | 0.08% | 26,162 | -75% | 0% | $63,050 |
| BARCLAYS PLC | 0.08% | 24,402 | +22% | 0% | $58,809 |
| BAKER BROS. ADVISORS LP | 0.07% | 22,809 | 0% | 0% | $54,970 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 18,610,735 | $44,851,327 | +$2,807,440 | $2.41 | 48 |
| 2025 Q3 | 17,461,169 | $31,603,874 | -$171,329 | $1.81 | 45 |
| 2025 Q2 | 17,802,633 | $21,184,501 | -$10,332,852 | $1.19 | 52 |
| 2025 Q1 | 22,517,048 | $45,710,668 | -$2,113,900 | $2.03 | 60 |
| 2024 Q4 | 23,250,351 | $139,966,100 | -$971,335 | $6.02 | 60 |
| 2024 Q3 | 22,960,755 | $160,726,039 | -$2,679,680 | $7.00 | 51 |
| 2024 Q2 | 23,451,873 | $136,019,583 | +$47,352,617 | $5.80 | 51 |
| 2024 Q1 | 15,245,438 | $109,005,559 | +$3,386,877 | $7.15 | 45 |
| 2023 Q4 | 14,865,624 | $73,138,289 | +$986,082 | $4.92 | 40 |
| 2023 Q3 | 15,093,861 | $144,297,342 | -$326,020 | $9.56 | 43 |
| 2023 Q2 | 15,126,531 | $196,038,750 | -$1,147,208 | $12.96 | 40 |
| 2023 Q1 | 15,216,182 | $191,059,725 | +$6,824,894 | $12.69 | 39 |
| 2022 Q4 | 14,965,637 | $170,360,092 | +$170,360,092 | $11.52 | 18 |